DYN241220C65000
- 0.25
- 0.000.00%
Dyne Therapeutics Newsroom
Piper Sandler Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $53
Dyne Therapeutics Initiated at Outperform by RBC Capital
Dyne Therapeutics Analyst Ratings
RBC Capital Initiates Dyne Therapeutics(DYN.US) With Buy Rating, Announces Target Price $45
Form 144 | Dyne Therapeutics(DYN.US) Insider Proposes to Sell 49.25 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Nov 14, $Dyne Therapeutics(DYN.US)$ Insider ForDyne B.V. intends to sell 1.5 million shares of its common stock on Nov 14, with a total market value of approximately $49.25
Dyne Therapeutics Reveals Q3 Results and Trial Updates
Dyne Therapeutics Is Maintained at Buy by Chardan Capital
Oppenheimer Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Oppenheimer Sticks to Their Buy Rating for Dyne Therapeutics (DYN)
Express News | Dyne Therapeutics Inc : Raymond James Cuts Target Price to $49 From $56
H.C. Wainwright Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $55
Dyne Therapeutics Receives Buy Rating Following IND Clearance and Promising Trial Updates
Morgan Stanley Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $52
Dyne Therapeutics | 10-Q: Q3 2024 Earnings Report
Dyne Therapeutics | 8-K: Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Express News | Dyne Therapeutics' Cash, Cash Equivalents And Marketable Securities Were $723.7M As Of September 30, 2024, Which Is Anticipated To Fund Operations At Least Into The Second Half Of 2026
Dyne Therapeutics Reports Q3 EPS (96c), Consensus (71c)
Press Release: Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Dyne Therapeutics 3Q Loss $97.1M >DYN
Express News | Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update